We are live on ! Find out more
BPMC

Blueprint Medicines
BPMC

Delisted

BPMC was delisted on the 17th of July, 2025.

Back to rankings

219 hedge funds and large institutions have $3.78B invested in Blueprint Medicines in 2019 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 87 increasing their positions, 56 reducing their positions, and 29 closing their positions.

New
Increased
Maintained
Reduced
Closed

209% more call options, than puts

Call options by funds: $90.8M | Put options by funds: $29.4M

55% more repeat investments, than reductions

Existing positions increased: 87 | Existing positions reduced: 56

3.21% more ownership

Funds ownership: 101.52% → 104.73% (+3.2%)

0% more funds holding in top 10

Funds holding in top 10: 8 → 8 (0)

0% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 29

0% less funds holding

Funds holding: 220 → 219 (-1)

19% less capital invested

Capital invested by funds: $4.68B → $3.78B (-$898M)

Holders
219
Holders Change
-1
Holders Change %
-0.45%
% of All Funds
4.8%
Holding in Top 10
8
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.18%
New
29
Increased
87
Reduced
56
Closed
29
Calls
$90.8M
Puts
$29.4M
Net Calls
+$61.4M
Net Calls Change
+$37.8M

Top Buyers

Rank Fund Capital Flow
1
CCM
Cadian Capital Management
New York
+$77.4M
2
Viking Global Investors
Viking Global Investors
Connecticut
+$21.7M
3
Westfield Capital Management
Westfield Capital Management
Massachusetts
+$20.3M
4
HM
HealthCor Management
New York
+$19.6M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$18.2M

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$28.5M
2
Invesco
Invesco
Georgia
-$24.3M
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$21.1M
4
AG
Artal Group
Luxembourg
-$13M
5
Federated Hermes
Federated Hermes
Pennsylvania
-$12.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
AL
126
AJO LP
Pennsylvania
$821K -$40.1K -464 -4%
ARTA
127
A.R.T. Advisors
New York
$821K +$657K +7,600 +212%
FT
128
Fiduciary Trust
Massachusetts
$819K – – –
AI
129
Axiom Investors
Connecticut
$767K -$855K -9,888 -49%
BG
130
Bollard Group
Massachusetts
$735K +$864K +10,000 New
CSS
131
Cubist Systematic Strategies
Connecticut
$735K +$865K +10,008 New
Mirae Asset Global Investments
132
Mirae Asset Global Investments
South Korea
$700K +$529K +6,120 +180%
AQR Capital Management
133
AQR Capital Management
Connecticut
$665K -$25.3K -293 -3%
BNP Paribas Financial Markets
134
BNP Paribas Financial Markets
France
$660K +$244K +2,828 +46%
RJA
135
Raymond James & Associates
Florida
$644K +$64.1K +741 +9%
AB
136
Amalgamated Bank
New York
$635K -$10.5K -121 -1%
CEP
137
Chicago Equity Partners
Illinois
$625K +$736K +8,510 New
AG
138
Aperio Group
California
$603K +$53.9K +624 +8%
TAM
139
Tocqueville Asset Management
New York
$575K +$56.2K +650 +9%
KAM
140
Kazazian Asset Management
Florida
$563K – – –
XK
141
Xact Kapitalforvaltning
Sweden
$555K – – –
SO
142
STRS Ohio
Ohio
$543K – – –
TAM
143
Tiverton Asset Management
Delaware
$542K – – –
SWRP
144
Summit Wealth & Retirement Planning
California
$540K – – –
ZCA
145
Zeke Capital Advisors
Pennsylvania
$532K +$166K +1,915 +36%
AC
146
Athanor Capital
New York
$500K +$147K +1,700 +33%
OPPM
147
Opus Point Partners Management
New York
$498K – – –
CIM
148
CIM Investment Management
Pennsylvania
$437K +$514K +5,946 New
WCM Investment Management
149
WCM Investment Management
California
$404K – – –
PNC Financial Services Group
150
PNC Financial Services Group
Pennsylvania
$402K +$43.2K +500 +10%
4 5
6
7 8

BPMC Hedge Fund Activity: Q3 2019 in Review

219 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q3 2019, worth a combined $3.78B — down 19% from $4.68B a quarter earlier.

Fund positioning in BPMC was balanced in Q3 2019: 29 funds opened new positions, 29 closed out, 87 added to existing stakes and 56 trimmed.

The largest buyer was Cadian Capital Management, adding an estimated $77.4M. The largest seller was Perceptive Advisors, cutting an estimated $28.5M.

  • 219 institutional investors held Blueprint Medicines (BPMC) as of Q3 2019, down from 220 in Q2 2019.
  • Funds reported $3.78B of Blueprint Medicines stock for Q3 2019, down 19% quarter-over-quarter.
  • 29 funds opened new Blueprint Medicines positions in Q3 2019 and 29 closed out, a net change of 0 holders.
  • The largest Blueprint Medicines buyer in Q3 2019 was Cadian Capital Management, an estimated $77.4M added.
  • The largest Blueprint Medicines seller in Q3 2019 was Perceptive Advisors, an estimated $28.5M sold.

Based on aggregated 13F filings for Q3 2019.